Branded Generics Global Market Report 2024

The branded generics market size has grown strongly in recent years. It will grow from $335.98 billion in 2023 to $367.67 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. Historical growth was driven by factors such as cost efficiencies, patent expirations, market reach expansion, government-driven initiatives, and healthcare policy reforms.

The branded generics market size is expected to see rapid growth in the next few years. It will grow to $542.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the upcoming period is linked to heightened demand for generic biologics, the increasing prevalence of chronic illnesses, expanding markets in emerging economies, and a dedicated emphasis on biosimilar products. Key trends expected in this forecast period comprise strategic partnerships and collaborations, technological advancements, a concentrated focus on chronic disease management, market consolidation, and a strong commitment to a patient-centric approach.

The burgeoning prevalence of chronic diseases is anticipated to fuel the expansion of the branded generics market. These enduring ailments, often incurable but manageable, are on the rise due to factors such as tobacco use, poor dietary habits, sedentary lifestyles, and excessive alcohol consumption. The global populace increasingly favors branded generics for treating chronic conditions, attracted by their cost-effectiveness compared to standard medications. Highlighting this trend, in September 2022, the World Health Organization (WHO) reported 41 million deaths worldwide, representing 74% of all noncommunicable disease (NCD) fatalities annually. This upsurge in chronic diseases is poised to elevate the demand for branded generics in the foreseeable future.

The escalating need within the pharmaceutical sector is set to propel the ascent of the branded generics market. This industry, dedicated to drug research, development, production, and marketing for medical purposes, leans on branded generics as an economical alternative to branded drugs. Additionally, these generics help sustain patient loyalty by offering a familiar, trusted product, even when the formulation is available as a generic. Notably, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA) in June 2023, the pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This surge in pharmaceutical demand underpins the growth of the branded generics market.

In December 2021 witnessed Biocon Ltd., an India-based biopharmaceutical entity, forging a strategic alliance with Tabuk Pharmaceuticals. This collaboration marks Biocon's foray into the MENA region encompassing Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. The intent behind this partnership is to curate an extensive global product portfolio aimed at providing cost-effective treatments to patients worldwide. Tabuk Pharmaceuticals, rooted in Saudi Arabia, will take charge of marketing authorization, registration, importation, and promotion of these medications within Saudi Arabia and adjoining Middle Eastern countries.

In June 2022, Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm specializing in branded generics, completed the acquisition of branded and generic injectable products from Eton Pharmaceuticals, Inc., a US-based pharmaceutical company. This transaction, valued at $50 million, serves Dr. Reddy's Laboratories' strategic agenda to expedite and broaden the availability of affordable medications. The acquisition includes notable products such as Biorphen (phenylephrine hydrochloride) injection and Rezipres, augmenting their efforts to introduce biosimilars into the market.

In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products.

Major companies operating in the branded generics market report are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International PLC, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

North America was the largest region in the branded generics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Branded generics encompass several drug classes, such as alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and others. Alkylating agents within branded generics are a subset of anticancer medications that impede DNA-to-RNA conversion, effectively disrupting protein synthesis. These chemicals modify hydrogen atoms on DNA to alkyl groups, inducing cross-links within the DNA strand, leading to cytotoxic, mutagenic, and carcinogenic effects. Branded generics offer various administration routes including topical, oral, parenteral, and others. They cater to diverse medical conditions encompassing oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal ailments, dermatological conditions, analgesics, anti-inflammatory treatments, and more.

The branded generics market research report is one of a series of new reports that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.